Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
When the term MIGS was first coined more than a decade ago, there were only a few options in the space. Since then, the MIGS space has grown significantly with many options addressing the same outflow pathway. As such, it might be time to start talking about MIGS in terms of procedural categories.
Innovation is changing the philosophy of glaucoma treatment from a drop-dependent approach to an interventional, procedure-based approach, according to Savak Teymoorian, MD. Where he’s found the philosophy shift toward acceptance of interventional glaucoma among patients has been with Durysta (bimatoprost intracameral implant, Allergan).
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ NDA submitted to FDA for once-daily glaucoma drop ➤ Positive Phase 3 data for novel preservative-free latanoprost delivery method ➤ Phase 4 DME safety study reduces need for treatments ➤ New data from Phase 3 trial for investigational Acanthamoeba keratitis treatment ➤ New findings on visual potential for adults with Leber congenital amaurosis ➤ ASCRS news and events
➤ FDA approves new therapy for amblyopia ➤ First-in-human data from IOL/drug-delivery platform ➤ Largest crosslinking study to date for keratoconus ➤ Interim data for Phase 2 trial evaluating choroidal melanoma treatment ➤ Gene therapy update ➤ SLT trial seeking more clinical sites, deadline October 14 ➤ Acquisition news ➤ ASCRS news and events
While some studies have found that femtosecond laser-assisted cataract surgery does not offer a significant benefit over traditional phaco, many surgeons still find it helpful in the setting of certain comorbidities. For Robert Noecker, MD, one of these is glaucoma.
➤ FDA approves new ocular surface anesthesia gel ➤ New drop approved to reduce IOP ➤ Newly available IOL incorporates technology that minimizes visual disturbances ➤ Interim data from Phase 1 trial for intravitreal implant to treat AMD ➤ Multiparty financing solution brought to ophthalmic practices ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline data for travoprost implant ➤ Enrollment complete for dry AMD interventional trial ➤ European Commission approves new treatment for wet AMD and DME ➤ Interim results for first-in-human trial with new glaucoma implant ➤ Three non-antibiotic drugs identified to treat ocular infection ➤ ASCRS news and events
While there has been a revolution within the last decade in terms of glaucoma management—surgical and medical—one expert would argue that trabeculectomy is still the most basic of glaucoma management procedures.
➤ Autologous stem cell therapy to treat dry AMD ➤ Topline results from Phase 3 trial for GA therapy ➤ Update on Phase 3 myopia progression clinical trial ➤ FDA accepts NDA application for investigational dry eye therapy ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.